BIT
$5M8mo
Biotron
Biotechnology · Infectious disease
Clinical-stage biotechnology company developing small-molecule antiviral drugs targeting viroporin proteins, with lead candidate BIT225 in Phase 2 for HIV-1.
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$1.8M
Mar 2026 4C
Runway
8moCAUTION
Based on Mar 2026 4C
Market Cap
$5M
Burn Rate
$0.7M/qtr
Mar 2026 4C
Shares Outstanding
2.7B
Pipeline Assets
2
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveOther3 June 2026
$525K R&D Rebate Received
Biotron Limited received an R&D Tax Incentive rebate of $525,869 for FY2024/25 from the Australian Government, representing 43.5% of eligible R&D expenditure on antiviral drug development programs. This is a cash rebate under the government's R&D Tax Incentive scheme.
3M Price
BIT.ASX$0.002-33.3% 3M
Low $0.002High $0.003
Pipeline Assets (2)
Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Catalysts (3)· 2 upcoming · 1 past
BIT225 licensing/partnership deal (via C14 advisory)
UpcomingSpeculativearrow_upwardHigh30 June 2026
HBV preclinical efficacy data from animal models
UpcomingExpectedremoveMed30 June 2026
expand_more1 past catalyst
Completed
Confirmed
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
1/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High72/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 1 of 1 guided dates· rolling 2yr(limited sample)· of 3 tracked
Filed 1 of 1 4Cs on time· statutory deadline· 2 filings without matched announcement
What drove these scores · rolling 2yr
arrow_drop_down
1 burn spike — Quarter-on-quarter spend increase >50%
arrow_drop_down
High admin overhead — Only 34% of opex directed to R&D
arrow_drop_up
Cash position improving — Cash balance grew over last 3 quarters
·
Mixed cash flow — Burn volatility calculated from 2 burning quarters only
Completed catalysts
✓$525K R&D Rebate Received— Biotron Limited received an R&D Tax Incentive rebate of $525,869 for FY2024/25 from the Australian Government, representing 43.5% of eligible R&D expenditure on antiviral drug development programs. This is a cash rebate under the government's R&D Tax Incentive scheme.
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Announcements(10)
payments
Quarterly 4CPSauto_awesome
Quarterly Activities/Appendix 4C Cash Flow Report29 Apr 2026
expand_more367KB